A phase I/II study evaluating safety and efficacy of autologous hematopoietic stem and progenitor cells genetically modified with IDUA lentiviral vector encoding for the human a-L-iduronidase gene for the treatment of patients affected by Mucopolysaccharidosis Type I, Hurler variant - TigetT10_MPS1H

OSPEDALE SAN RAFFAELE0 sites6 target enrollmentMarch 9, 2020

Overview

No summary available.

Registry

who.int

Start Date

March 9, 2020

End Date

TBD

Last Updated

5 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Sponsor

OSPEDALE SAN RAFFAELE

•1\.Written informed consent by parent/legal guardian
•2\. Sex: Males or Females
•3\. Age: \= 28 days and \= 11 years old
•4\. Biochemically and molecularly proven MPS IH
•5\.Lansky Index \> 80 %
•6\.Indication to HSCT
•7\.Lack of a non\-heterozygous (for mutated IDUA) HLA\-matched sibling donor or a \=7/8 (4 digits high\-resolution typing) HLA\-matched cord blood donor with a cellularity \=5 x 107 Total Nucleated Cells (TNC)/Kg after 1\-month search
•8\.Adequate cardiac, renal, hepatic and pulmonary functions
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 1

•1\.Use of other investigational agents within 4 weeks prior to study enrolment (within 6 weeks if use of long\-acting agents)
•2\.Severe, active viral, bacterial, or fungal infection at eligibility evaluation
•3\.Patients affected by malignant neoplasia or family history of familial cancer syndromes
•4\.Cytogenetic alterations associated with high risk of developing hematological malignancies
•5\.History of uncontrolled seizures
•6\.Patients with end\-organ damage or any other severe disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study
•7\.Positivity for HIV (serology or RNA), and/or HbsAg and/or HBV DNA and/or HCV RNA and/or Treponema Pallidum or Mycoplasma active infection
•8\.Patients with DQ/IQ \<70
•9\.Previous allogeneic HSCT or gene therapy with a different product
•10\. Controindications to PeIMP (G\-CSF, Plerixafor, Busulfan, Fludarabine, Rituximab)